Istituto Biochimico Italiano

What Istituto Biochimico Italiano does

Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (IBI) is a privately held Italian pharmaceutical company founded in 1918 and headquartered in Aprilia, operating as part of the IBIGEN Pharmaceutical Group under third-generation family stewardship. The company is a vertically integrated manufacturer specializing in sterile injectable products, with deep expertise in aseptic filling, β-lactam antibiotic production (crystallization and freeze-drying at 150,000 kg/year capacity, ~45 million vials/year), and biotechnology including monoclonal antibodies, biosimilars, and recombinant proteins via CHO and E.coli platforms. It holds FDA approval since 1961 (one of the first non-US companies) along with AIFA, TGA, MHRA, EMA, EU GMP, and ISO certifications, and has invested €50 million in Industry 4.0 serialization and traceability.

IBI generates revenue through four primary streams: (1) proprietary finished pharmaceutical products (injectable antibiotics, antifungals, anesthetics, and gastroenterology/pain products) sold under the IBISQUS hospital brand in Italy, Germany, UK, and Ireland through wholly-owned subsidiaries; (2) retail pharmacy products in Italy including OTC medications (METEOSIM, IBIFEN), supplements (REALSIL line), and medical devices; (3) API and finished-product exports to 20 countries with 80% of production exported and two-thirds of foreign revenue from the US; and (4) Contract Development and Manufacturing Organization (CDMO) services covering cGMP biologics, nanoparticle formulations, clinical trial batches, and IN/OUT licensing for European, US, and Asian partners. Pricing is quote-based; the customer mix spans hospital procurement, retail pharmacy, international distributors, and biotech/pharma CDMO clients.

Name

Istituto Biochimico Italiano

Legal name

Istituto Biochimico Italiano Giovanni Lorenzini S.p.A.

Website

https://ibi-lorenzini.it

Company type

Private

Founded year

1918

Operating status

Operating

Headcount range

251–500 employees

Short description

Istituto Biochimico Italiano is an Italian family-owned pharmaceutical manufacturer producing sterile injectable β-lactam antibiotics, biologics, and CDMO services for hospitals, retail pharmacies, and international distributors across 20 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Aprilia

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Finished Pharmaceutical Products Sales: Sale of proprietary pharmaceutical products including antibiotics, gastroenterology drugs, anti-inflammatory medications through hospital and retail pharmacy channels in Italy and internationally
2. Active Pharmaceutical Ingredients (API) Export: Export of sterile penicillin and other antibiotic APIs to 20 countries including USA, certified to major regulatory standards (FDA, TGA, AIFA)
3. Contract Development and Manufacturing (CDMO): GMP development and manufacturing services for pharmaceutical companies, biotech startups, and research centers including process development, analytical validation, stability studies, and clinical trial batch production
4. IN/OUT Licensing: Licensing agreements for proprietary products to international partners and in-licensing of new products through Business Development and Export departments

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

IBI is a vertically integrated pharmaceutical manufacturer that produces and sells sterile injectable products (antibiotics, β-lactam penicillins, hospital anesthetics, antifungals, and gastroenterology medications) to hospitals and retail pharmacies in Italy, Germany, the UK, and 20+ export countries. Beyond its proprietary portfolio, IBI offers Contract Development and Manufacturing (CDMO) services covering sterile injectables, lyophilized products, monoclonal antibodies, recombinant proteins, nanomedicine formulations, and clinical-trial batches for pharma and biotech clients. Its main 18,000 sqm cGMP production facility is in Aprilia, Italy, with direct sales subsidiaries in Italy (IBISQUS), Germany (Ibisqus GmbH), and the UK/Ireland (Bowmed Ibisqus).

Product overview

Istituto Biochimico Italiano (IBI) is a vertically integrated pharmaceutical company producing and selling injectable products for over 100 years. The portfolio comprises hospital injectable products (antibiotics, anesthetics, antifungals) distributed under the IBISQUS brand in Italy, Germany, UK, and Ireland; retail pharmacy products including OTC medications (METEOSIM, IBIFEN), supplements (REALSIL line), and medical devices; and export products. IBI operates as a CDMO offering contract development and manufacturing services including biologics, nanoparticle formulations, and clinical trial production. The company specializes in sterile penicillin and beta-lactam injectable products with dedicated production facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Realsil: Nutritional supplement line containing Milk Thistle (Silybum marianum) extract with phospholipids and vitamins D and E for liver support
• Realsil100D
• Meteosim
• IBIFEN
• Laxido

Products and services

• IBISQUS Hospital Line Hospital product distribution brand distributing injectable antibiotics, anesthetics, antifungals, and other hospital therapies in Italy, Germany, UK, and Ireland. Includes key products such as Amoxicillina e Acido Clavulanico IBIGEN, Piperacillina e Tazobactam IBIGEN, Teicoplanina IBIGEN, Voriconazolo IBISQUS, Midazolam IBI, Gabesato Mesilato IBI, Atosiban IBISQUS, and Ripol anesthetic emulsion.
• Contract Development and Manufacturing Services (CDM) Comprehensive CDMO services including GMP development and manufacturing of biotechnological active ingredients, proteins and monoclonal antibodies; oral, topical, and injectable formulations; nanoparticle-based innovative formulations; analytical methods development; process scaling and transfer; clinical trial batch production; and regulatory support.
• Biotechnology Services Development and GMP production of monoclonal antibodies (mAbs), biosimilars, recombinant proteins, and New Biological Entities (NBEs) using CHO cell expression platforms and E.coli systems.
• Biopharmaceutical R&D Services Pharmaceutical development services including process development for biological APIs, formulation development, analytical development, and technology transfer using Quality by Design (QbD) and DoE approaches for process optimization and regulatory documentation.
• Finished Products Manufacturing cGMP manufacturing of sterile products (solutions, freeze-dried powders, aseptic doses) and non-sterile products (oral and topical). Specializes in injectable β-lactam drugs with dedicated segregated production areas.
• IN and OUT Licensing Licensing services for pharmaceutical products across gastroenterology, inflammation and pain, nutraceuticals, and anti-infectives. Markets registered in Europe, USA, and Asia through international partners, managed via Business Development and Export departments.
• METEOSIM

Quantifiable outcome

• 80% of production exported to 20 countries
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core, minor and strategic.

• AllecracoreStrategic or Co-development PartnerCDM services customer for pharmaceutical contract development and manufacturing
• AlfasigmacoreStrategic or Co-development PartnerCDM services customer for pharmaceutical contract development and manufacturing
• Kuros BiosciencescoreStrategic or Co-development PartnerBiotechnology company using IBI's CDMO services for biotech product development
• Magna Graecia University of CatanzarominorStrategic or Co-development PartnerAcademic research center using CDMO services for university research projects
• Rockwell AutomationcoreTechnology or IntegrationTechnology provider for Pharma Suite serialization software enabling drug identification and traceability for Industry 4.0 compliance
• European Commission (Horizon 2020)strategicStrategic or Co-development PartnerEU-funded research partner in Horizon 2020 projects B-Smart (nanomedicine) and NanoGSkin for nanoparticle delivery system development from lab to GMP production
• LAZIO INNOVAstrategicStrategic or Co-development PartnerRegional funding partner for LIFE2020 and KETS innovation projects
• DHL Supply Chain ItalyminorOthersLogistics partner for hospital product order transmission and distribution in Italy

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Recordati: Larger publicly-listed Italian pharmaceutical company with specialty/hospital product lines across Europe. Comparable therapeutic areas (gastroenterology, rare disease) but significantly broader portfolio, larger scale, and public-market capital access.
• Catalent: Global CDMO with extensive sterile injectable, biologic, and softgel manufacturing services. Comparable in CDMO offerings for injectables and biologics, but operates at substantially larger scale with global manufacturing footprint.
• Hospira (Pfizer CentreOne): Major global manufacturer of sterile injectable pharmaceuticals and injectable generics, now part of Pfizer. Comparable in sterile injectable antibiotics and hospital injectables, but at vastly greater scale and broader therapeutic breadth.

Direct peers

• Fareva: European CDMO with sterile injectable and finished-dose manufacturing capabilities for pharma and biotech clients. Directly comparable in CDMO service offering for sterile injectables, GMP manufacturing, and European footprint.
• Recipharm: European CDMO with significant sterile injectable manufacturing capacity serving pharma and biotech clients. Comparable in CDMO services for injectables, lyophilized products, and clinical/commercial manufacturing across multiple European sites.
• Menarini: Italy's largest privately-held pharmaceutical company, with hospital injectables, antibiotics, and international distribution across Europe. Comparable in Italian privately-held family ownership, hospital pharmaceutical portfolio, and European commercial footprint.
• Fidia Farmaceutici: Italian mid-sized pharmaceutical company with proprietary products in gastroenterology, joint care, and hospital specialties. Closely comparable in therapeutic focus (gastroenterology, hepatology), Italian family-controlled structure, and hospital/retail dual-channel go-to-market.
• Olon S.p.A. Italian API and CDMO company specializing in antibiotic and fermentation-derived APIs, with global manufacturing footprint. Comparable in scale, Italian heritage, antibiotic API focus, and contract development services for injectable finished forms.
• ACS Dobfar: Italian-headquartered manufacturer of sterile β-lactam antibiotics and APIs, with similar vertical integration, FDA-inspected facilities, and a comparable mix of proprietary and CDMO business. Direct overlap in sterile penicillin and cephalosporin injectable manufacturing.
• Molteni & C. dei Fratelli Alitti: Italian specialty pharma focused on sterile injectable hospital products, including analgesics and addiction-treatment medications. Comparable in size, Italian origin, and emphasis on aseptic injectable manufacturing for hospital distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC-_ThQamMVWRCVDHOO0jnNQ
• LinkedInlinkedin.com/company/istituto-biochimico-italiano-giovanni-lorenzini-s.p.a.

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Istituto Biochimico Italiano